An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease.
Phase of Trial: Phase III
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors IMPAX Laboratories
- 15 Mar 2013 Data will be presented at the 65th Annual Meeting of the American Academy of Neurology (AAN-2013), according to an Impax Pharmaceuticals media release.
- 24 Jul 2012 Actual end date Oct 2011 added as reported by ClinicalTrials.gov.
- 01 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.